Supplemental Table 1. Complete blood count of CT and EC-Myc KO mice.

Test	CT	EC-Myc KO	p-value
White Blood Cell Count (10^3/µL)	2.17 ± 0.75	2.27 ± 0.81	0.828
Red Blood Cell Count (10^6/µL)	8.23 ± 0.60	8.32 ± 0.71	0.814
Hemoglobin (g/dL)	11.02 ± 0.72	11.08 ± 0.83	0.885
Hematocrit (%)	39.33 ± 3.67	40.00 ± 2.37	0.716
MCV (fL)	48.00 ± 1.10	48.00 ± 1.41	1.000
MCH (pg)	13.50 ± 0.55	13.33 ± 0.52	0.599
MCHC (%)	28.17 ± 1.17	27.83 ± 0.75	0.570
Neutrophils Count (10^3/µL)	0.42 ± 0.32	0.52 ± 0.33	0.618
Neutrophils (%)	15.80 ± 4.87	21.17 ± 9.64	0.290
Lymphocytes Count (10^3/µL)	1.57 ± 0.71	1.46 ± 0.47	0.766
Lymphocytes (%)	78.40 ± 6.07	66.17 ± 10.76	0.051
Monocytes Count (10^3/µL)	0.17 ± 0.08	0.26 ± 0.14	0.172
Monocytes (%)	7.67 ± 2.66	11.33 ± 2.80	**0.045***
Eosinophils Count (10^3/µL)	0.017 ± 0.010	0.025 ± 0.030	0.536
Eosinophils (%)	0.83 ± 0.41	1.17 ± 1.60	0.632

Results are expressed as mean ± standard deviation (n = 6). CT, control; EC-Myc KO, endothelial c-Myc knockout; MCV, mean corpuscular volume; MCH, mean cell hemoglobin; MCHC, mean corpuscular hemoglobin concentration. *$p<0.05$.

Supplemental Table 2. Flow cytometry analysis of bone marrow cells from CT and EC-Myc KO mice.

Cell Type	Male		Female	
	CT	EC-Myc KO	CT	EC-Myc KO
Long Term Hematopoietic Stem cell (LT-HSC)	0.0076 ± 0.0016	0.0049 ± 0.0027	0.021 ± 0.026	0.022 ± 0.015
Short Term Hematopoietic Stem cell (ST-HSC)	0.0118 ± 0.0046	0.0136 ± 0.0061	0.074 ± 0.034*	0.069 ± 0.020§
Multipotent Progenitors (MMP)	0.146 ± 0.028	0.144 ± 0.057	0.274 ± 0.099*	0.266 ± 0.050§
Lymphoid Progenitors (LP)	0.060 ± 0.015	0.063 ± 0.036	0.166 ± 0.070*	0.146 ± 0.036§
Common Myeloid Progenitors (CMP)	0.112 ± 0.016	0.098 ± 0.013	0.074 ± 0.009*	0.057 ± 0.021§
Granulocyte-Monocyte Progenitors (GMP)	0.240 ± 0.023	0.204 ± 0.030	0.210 ± 0.055	0.204 ± 0.013
Megakaryocyte-Erythroid Progenitors (MEP)	0.310 ± 0.084	0.292 ± 0.073	0.176 ± 0.024*	0.224 ± 0.038
Granulocytes	52.7 ± 8.0	49.8 ± 7.4	48.1 ± 7.3	41.6 ± 3.5
Erythrocytes	10.1 ± 4.0	11.5 ± 4.0	5.9 ± 2.0	9.3 ± 2.5
Monocytes/Macrophages	5.30 ± 0.78	4.40 ± 0.62	3.72 ± 0.83*	3.41 ± 0.82
B Lymphocytes	4.94 ± 1.57	5.01 ± 1.99	6.07 ± 1.98	7.24 ± 2.34
CD4+ T Lymphocytes	0.38 ± 0.09	0.43 ± 0.26	0.20 ± 0.03	0.28 ± 0.20
CD8+ T Lymphocytes	0.42 ± 0.15	0.37 ± 0.19	0.11 ± 0.20	0.25 ± 0.51
NK cells	0.35 ± 0.12	0.39 ± 0.05	0.40 ± 0.13	0.45 ± 0.09

Values represent percentage of different cell types. Results are expressed as mean ± standard deviation (n = 5). CT, control; EC-Myc KO, endothelial c-Myc knockout. *$p<0.05$ between genders within CT; §$p<0.05$ between genders within EC-Myc KO.

Supplemental Table 3. Multiplex analysis of serum samples from CT and EC-Myc KO mice.

Target	CT	EC-Myc KO	p-value
CCL2	n.d.	n.d.	
CCL3	n.d.	n.d.	
CCL4	n.d.	n.d.	
CCL5	n.d.	n.d.	
CCL7	37 ± 19	74 ± 40	**0.012***
CCL11	761 ± 315	743 ± 492	0.920
CCL12	85 ± 67	75 ± 28	0.661
CCL21	2291 ± 700	2875 ± 2494	0.463
TNFSF11	121 ± 21	90 ± 24	**0.004****
TWEAK	n.d.	n.d.	
IL1β	n.d.	n.d.	
IL6	n.d.	n.d.	
IL-5	n.d.	n.d.	
IL-16	519 ± 255	563 ± 206	0.662
Osteopontin	139986 ± 17031	197414 ± 65967	**0.011***

Values represent concentration in pg/ml calculated using standard curves for each marker. Results are expressed as mean ± standard deviation (n = 11). CT, control; EC-Myc KO, endothelial c-Myc knockout; n.d., not detected. *$p<0.05$, **$p<0.01$.

Supplemental Table 4. Phenotypic analysis of CT and EC-Myc KO mice after long-term exposure to HFD.

Male	CT-CTD	EC-Myc KO-CTD	CT-HFD	EC-Myc KO-HFD
Body Weight (g)	32.8 ± 3.7	37.6 ± 4.5*	27.2 ± 3.2†	27.9 ± 4.2‡
Liver Weight (g)	1.26 ± 0.20	1.49 ± 0.22	1.91 ± 0.25†	2.00 ± 0.30‡
Liver/Body Weight Ratio	0.038 ± 0.004	0.039 ± 0.002	0.071 ± 0.011†	0.073 ± 0.013‡
Plasma Triglycerides (mg/dL)	56 ± 15	65 ± 20	55 ± 13	58 ± 14
Plasma Cholesterol (mg/dL)	104 ± 15	119 ± 17	150 ± 29†	**177 ± 38§‡**
Liver Triglycerides (mg/g tissue)	17.2 ± 14.1	30.1 ± 13.2	19.1 ± 5.5	21.3 ± 8.8
Liver Cholesterol (mg/g tissue)	3.03 ± 0.67	3.34 ± 0.61	22.67 ± 7.07†	21.54 ± 6.80‡
Female	**CT-CTD**	**EC-Myc KO-CTD**	**CT-HFD**	**EC-Myc KO-HFD**
Body Weight (g)	22.1 ± 1.4	23.2 ± 3.1	21.7 ± 1.5	22.2 ± 2.0
Liver Weight (g)	0.87 ± 0.09	0.92 ± 0.15	1.86 ± 0.24†	1.93 ± 0.21‡
Liver/Body Weight Ratio	0.040 ± 0.004	0.039 ± 0.003	0.086 ± 0.006†	0.087 ± 0.006‡
Plasma Triglycerides (mg/dL)	67 ± 21	67 ± 25	75 ± 29	55 ± 24
Plasma Cholesterol (mg/dL)	78 ± 12	81 ± 12	160 ± 41†	**191 ± 27§‡**
Liver Triglycerides (mg/g tissue)	26.2 ± 5.0	24.7 ± 8.3	20.3 ± 2.1	21.6 ± 5.5
Liver Cholesterol (mg/g tissue)	4.35 ± 0.50	3.55 ± 0.52	30.75 ± 2.30†	31.20 ± 4.54‡

Results were collected after long-term exposure to experimental diet and are expressed as mean ± standard deviation (n = 8-13). CT, control; EC-Myc KO, endothelial c-Myc knockout; CTD, low-fat control diet; HFD, high-fat diet. *$p<0.05$ between genotypes within CTD; $^{\dagger}p<0.05$ between diets within CT; $^{\ddagger}p<0.05$ between diets within EC-Myc KO; $^{\S}p<0.05$ between genotypes within HFD.

Supplemental Table 5. Multiplex analysis of liver lysates from CT and EC-Myc KO mice after short-term exposure to HFD.

Target	Male		Female	
	CT	EC-Myc KO	CT	EC-Myc KO
Eotaxin/CCL11	11.9 ± 1.9	13.3 ± 3.3	13.6 ± 3.6	**18.4 ± 5.2*‡**
G-CSF	0.81 ± 0.92	0.73 ± 0.49	0.85 ± 0.34	0.85 ± 0.45
GM-CSF	n.d.	n.d.	n.d.	n.d.
IFNγ	7.56 ± 1.78	8.79 ± 2.60	9.65 ± 0.89†	10.51 ± 1.73
IL-1α	158.7 ± 17.8	168.1 ± 18.0	177.8 ± 19.3†	191.0 ± 9.9‡
IL-1β	6.19 ± 2.17	5.95 ± 1.74	6.95 ± 1.62	7.83 ± 0.88‡
IL-2	32.7 ± 5.0	34.6 ± 7.3	36.5 ± 5.4	**43.4 ± 2.9*‡**
IL-3	0.35 ± 0.22	0.34 ± 0.15	0.35 ± 0.12	0.48 ± 0.20
IL-4	0.32 ± 0.12	0.32 ± 0.12	0.43 ± 0.13†	0.47 ± 0.05‡
IL-5	n.d.	n.d.	n.d.	n.d.
IL-6	1.55 ± 0.37	1.85 ± 0.84	1.94 ± 0.48	2.06 ± 0.67
IL-7	5.31 ± 1.53	5.69 ± 0.97	6.94 ± 0.65†	**8.26 ± 0.91*‡**
IL-9	43.0 ± 9.2	42.6 ± 9.8	50.8 ± 7.4	57.2 ± 7.6‡
IL-10	30.7 ± 10.8	35.3 ± 7.1	39.3 ± 8.4†	43.2 ± 4.4‡
IL-12p40	42.8 ± 18.7	51.5 ± 21.7	63.3 ± 18.9†	72.5 ± 13.6‡
IL-12p70	4.02 ± 2.97	3.89 ± 1.08	3.16 ± 1.37	4.01 ± 1.90
IL-13	1.81 ± 1.09	2.06 ± 0.71	2.70 ± 0.55†	3.35 ± 0.78‡
IL-15	23.2 ± 8.3	25.6 ± 6.4	31.8 ± 5.2†	**39.3 ± 6.3*‡**
IL-17	0.39 ± 0.04	0.42 ± 0.09	0.52 ± 0.04†	**0.60 ± 0.08*‡**
KC/CXCL1	53.0 ± 14.3	54.8 ± 5.8	58.7 ± 13.6	**70.4 ± 7.1*‡**
LIX/CXCL5	146.8 ± 67.5	141.8 ± 47.3	164.8 ± 56.7	201.0 ± 34.7‡
MCP-1/CCL2	16.9 ± 6.4	14.8 ± 7.0	17.1 ± 12.9	12.8 ± 5.5
M-CSF	2.00 ± 0.38	1.61 ± 0.38	1.92 ± 0.40	2.02 ± 0.41

MIP-1α/CCL3	25.4 ± 2.7	28.0 ± 3.0	27.8 ± 3.4	30.1 ± 2.5
MIP-1β/CCL4	n.d.	n.d.	n.d.	n.d.
MIP-2/CXCL2	195.2 ± 37.3	197.4 ± 42.9	213.1 ± 32.2	243.9 ± 27.1‡
RANTES/CCL5	3.20 ± 0.63	3.64 ± 1.15	4.14 ± 1.36	3.81 ± 0.75
TNFα	1.75 ± 0.34	1.43 ± 0.27	2.11 ± 0.64	2.37 ± 0.84‡
VEGF	14.5 ± 2.0	14.0 ± 1.3	14.8 ± 2.1	16.7 ± 3.8

Values represent concentration in pg/ug total protein calculated using standard curves for each marker. Results are expressed as mean ± standard deviation (n = 9-10). CT, control; EC-Myc KO, endothelial c-Myc knockout; n.d., not detected. *$p<0.05$ between genotypes within female; †$p<0.05$ between genders within CT; ‡$p<0.05$ between genders within EC-Myc KO.